Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global
commercial-stage biopharmaceutical company focused on transforming
the lives of patients and their families living with rare
neuroendocrine diseases, today reported financial results and
provided a business update for the first quarter ended March 31,
2024.
“We continue to execute our global strategy of delivering
IMCIVREE® (setmelanotide) to patients with hyperphagia and severe
obesity caused by rare melanocortin-4 receptor (MC4R) pathway
diseases,” said David Meeker, M.D., Chair, President and Chief
Executive Officer of Rhythm. “We had another solid quarter marked
by steady growth in global sales of IMCIVREE, which is now
available in 14 markets.”
Dr. Meeker continued, “We remain focused on expanding the global
opportunity for setmelanotide in additional indications, most
notably in hypothalamic obesity with our ongoing, global Phase 3
trial. This pivotal trial is progressing as planned, and we
anticipate dosing the first patients with hypothalamic obesity in
Japan in the second quarter of 2024. In addition, we expect to
submit a supplementary New Drug Application (sNDA) to the FDA
seeking a label expansion for IMCIVREE to treat pediatric patients
between 2 and younger than 6 years old in approved indications in
the second quarter of 2024. While we work to maximize the
setmelanotide opportunity, we are also advancing our broader MC4R
portfolio with continued progress with our RM-718 and LB54640
programs.”
First Quarter and Recent Business
Highlights
- Today, Rhythm announced that approximately 100 new
prescriptions for IMCIVREE for Bardet-Biedl syndrome (BBS) were
written by U.S. prescribers and that the Company has received payor
approval for reimbursement for approximately 70 prescriptions
during the first quarter of 2024.
- On May 2, Rhythm and its collaborators delivered one oral
presentation and two posters at The Pediatric Endocrine Society’s
(PES) Annual Meeting May 2-5, 2024 in Chicago, IL, which
highlighted previously disclosed data that showed setmelanotide
achieved clinically meaningful weight reduction in pediatric
patients with hypothalamic obesity, BBS or POMC and LEPR deficiency
obesities.
- On April 29, the Company announced the publication of results
from its Phase 2 study of setmelanotide for the treatment of
hypothalamic obesity in the peer-reviewed journal The Lancet
Diabetes & Endocrinology. The publication highlights that
setmelanotide achieved a mean percent reduction in BMI of 15% from
baseline at 16 weeks of therapy (N=18), and preliminary data from
Rhythm’s long-term extension study showing setmelanotide achieved
mean BMI reduction of approximately 26% at one year (n=12).
- On April 1, 2024, Rhythm announced an investment agreement with
current shareholders, led by Perceptive Advisors LLC and its
Discovery Fund and a life-sciences focused institutional investor,
for the sale of its series A convertible preferred stock
(“Preferred Stock”) for gross proceeds of $150 million to the
Company. This transaction closed on April 15, 2024.
- On March 25, Rhythm announced that the first patients had been
dosed in the Company’s Phase 1 clinical trial of RM-718, an
investigational, weekly MC4R agonist designed to be MC1R-sparing
and to potentially avoid hyperpigmentation.
Anticipated Upcoming Milestones
Rhythm expects to achieve the following near-term
milestones:
- Complete submission of a supplementary New Drug Application
(sNDA) to the FDA seeking a label expansion to treat pediatric
patients between 2 and younger than 6 years old in approved
indications in the second quarter of 2024, with EMA approval for
this pediatric expansion potentially in the fourth quarter of
2024;
- Begin dosing patients in the Japanese, 12-patient supplemental
cohort of the Phase 3 trial evaluating setmelanotide in
hypothalamic obesity in the second quarter of 2024;
- Begin dosing the first patients in the Phase 2 SIGNAL trial
evaluating LB54640, an investigational oral small molecule MC4R
agonist, in patients with hypothalamic obesity, in the third
quarter of 2024. The 28-patient SIGNAL trial is a randomized,
placebo-controlled, double-blind study designed to evaluate three
dose levels of LB54640. The primary endpoint of the study is the
change from baseline in body mass index after 14 weeks of
treatment, and patients may continue on therapy for up to 52
weeks;
- Announce data from stage 2 of the exploratory Phase 2 DAYBREAK
study evaluating setmelanotide in certain genetically-caused MC4R
pathway diseases in the third quarter of 2024;
- Complete enrollment in two or more substudies in the Phase 3
EMANATE trial evaluating setmelanotide in a total of four
genetically caused MC4R pathway diseases in the second half of
2024;
- Complete the Company’s Phase 1 clinical trial of RM-718, an
investigational, weekly MC4R-specific agonist, and announce data
from this trial – including data from a planned cohort of patients
with hypothalamic obesity - in the first half of 2025; and
- Announce top-line data in the Phase
3 trial evaluating setmelanotide in hypothalamic obesity in the
first half of 2025.
First Quarter and Full Year
2023 Financial Results:
- Cash Position: As of March 31, 2024,
cash, cash equivalents and short-term investments were
approximately $201 million, as compared to $275.8 million as
of December 31, 2023. This decrease in cash during the quarter
included $40 million for an up-front payment to LG Chem for global
rights to LB-54640 paid in January 2024. This cash on-hand amount
does not include gross proceeds of $150 million from the sale of
preferred stock during the second quarter.
- Revenue: Net product revenues relating to
sales of IMCIVREE were $26.0 million for the three months ended
March 31, 2024, as compared to $11.5 million for the three months
ended March 31, 2023. For the three months ended March 31, 2024 and
2023, a substantial amount of our product revenue, or 74% and 83%,
respectively, was generated from sales of our product in the United
States.
- R&D Expenses: R&D expenses were
$128.7 million for the three months ended March 31, 2024, as
compared to $37.9 million for the three months ended March 31,
2023. The year-over-year increase was primarily due to in-process
research and development costs totaling $92.4 million associated
with the acquisition of LG Chem’s proprietary compound LB54640.
Additional increased costs were associated with salaries, benefits
and stock-based compensation related to the hiring of additional
full-time employees, and clinical trial activities. These increases
were partially offset by the one-time costs recorded in the three
months ended March 31, 2023, for the purchase of research and
development assets from Xinvento, BV.
- S,G&A Expenses: S,G&A expenses
were $34.4 million for the three months ended March 31, 2024,
as compared to $24.6 million for the three months ended March 31,
2023. The year-over-year increase was primarily due to increased
compensation and benefits related costs associated with additional
headcount to support our expanding business operations and
commercial operations, increases in professional services and
consulting costs and increases in costs associated with ongoing
sales and marketing activities.
- Other income (expense), net: Other income
(expense), net decreased by $1.6 million to ($1.2) million for the
three months ended March 31, 2024, from $0.4 million for the three
months ended March 31, 2023, primarily due to an increase in
non-cash interest expense from amortization of debt discount and
deferred financing fees associated with a higher deferred royalty
obligation balance, and recognition of non-cash interest expense
associated with accretion of the non-current liability payable to
LG Chem in July 2025; this decrease was partially offset by an
increase in other income from the change in fair value of the
embedded derivative of $0.5 million associated with the Revenue
Interest Financing Agreement, or RIFA, entered into with HealthCare
Royalty Partners in June 2022.
- Net Loss: Net loss was $(141.4)
million for the three months ended March 31, 2024, or a net
loss per basic and diluted share of ($2.35), as compared to a
net loss of ($52.2) million for the three months ended March
31, 2023, or a net loss per basic and diluted share
of ($0.92).
Financial Guidance:
For the year ending December 31, 2024, Rhythm anticipates
approximately $250 million to $270 million in Non-GAAP Operating
Expenses. Non-GAAP Operating Expenses are derived from:
- GAAP total operating expenses, inclusive of:
- SG&A expenses of $105 million to $110 million; and
- R&D expenses of $145 million to $160 million,
- inclusive of $10 million to $15 million of LB54640 development
costs;
- but which excludes:
- Stock-based compensation, and
- $92.4 million in fixed consideration related to in-licensing of
global rights to LB54640, which was recognized in the first quarter
of 2024.
Non-GAAP Operating Expenses is defined
as GAAP operating expenses excluding stock-based compensation and
fixed consideration related to in-licensing (see below under
"Non-GAAP Financial Measures" for more details).
Based on its current operating plans,
Rhythm expects that its existing cash, cash equivalents and
short-term investments as of March 31, 2024 along with the proceeds
from the sale of $150 million in preferred stock, will be
sufficient to fund its operating expenses and capital expenditure
requirements into 2026.
Conference Call
InformationRhythm Pharmaceuticals will host a live
conference call and webcast at 8:00 a.m. ET today to review its
first quarter 2024 financial results and recent business
activities. Participants may register for the conference call here.
It is recommended that participants join the call ten minutes prior
to the scheduled start.
A live webcast of the call will also be available under "Events
and Presentations" in the Investor Relations section of the Rhythm
Pharmaceuticals website at https://ir.rhythmtx.com/. The archived
webcast will be available on Rhythm Pharmaceuticals’ website
approximately two hours after the conference call and will be
available for 30 days following the call.
About Rhythm PharmaceuticalsRhythm is a
commercial-stage biopharmaceutical company committed to
transforming the lives of patients and their families living with
rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE®
(setmelanotide), an MC4R agonist designed to treat hyperphagia and
severe obesity, is approved by the U.S. Food and Drug
Administration (FDA) for chronic weight management in adult and
pediatric patients 6 years of age and older with monogenic or
syndromic obesity due to proopiomelanocortin (POMC), proprotein
convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor
(LEPR) deficiency confirmed by genetic testing, or patients with a
clinical diagnosis of Bardet-Biedl syndrome (BBS). Both the
European Commission (EC) and the UK’s Medicines & Healthcare
Products Regulatory Agency (MHRA) have authorized setmelanotide for
the treatment of obesity and the control of hunger associated with
genetically confirmed BBS or genetically confirmed loss-of-function
biallelic POMC, including PCSK1, deficiency or biallelic LEPR
deficiency in adults and children 6 years of age and above.
Additionally, Rhythm is advancing a broad clinical development
program for setmelanotide in other rare diseases, as well as RM-718
and a preclinical suite of small molecules for the treatment of
congenital hyperinsulinism. Rhythm’s headquarters is in Boston,
MA.
Setmelanotide IndicationIn the United
States, setmelanotide is indicated for chronic weight management in
adult and pediatric patients 6 years of age and older with
monogenic or syndromic obesity due to POMC, PCSK1 or LEPR
deficiency as determined by an FDA-approved test demonstrating
variants in POMC, PCSK1 or LEPR genes that are interpreted as
pathogenic, likely pathogenic, or of uncertain significance (VUS)
or BBS.
In the European Union, setmelanotide is indicated for the
treatment of obesity and the control of hunger associated with
genetically confirmed Bardet-Biedl syndrome (BBS) or genetically
confirmed loss-of-function biallelic proopiomelanocortin (POMC),
including PCSK1, deficiency or biallelic leptin receptor (LEPR)
deficiency in adults and children 6 years of age and above.
Limitations of UseIn the United
States and Europe, Setmelanotide should be prescribed and
supervised by a physician with expertise in obesity with underlying
genetic etiology.
Setmelanotide is not indicated for the treatment of patients
with the following conditions as setmelanotide would not be
expected to be effective:
- Obesity due to suspected POMC, PCSK1 or LEPR deficiency
with POMC, PCSK1 or LEPR variants
classified as benign or likely benign
- Other types of obesity not related to POMC, PCSK1 or LEPR
deficiency, or BBS, including obesity associated with other genetic
syndromes and general (polygenic) obesity.
WARNINGS AND PRECAUTIONS
Skin Monitoring: Setmelanotide may lead to
generalized increased skin pigmentation and darkening of
pre-existing naevi because of its pharmacologic effect. Full body
skin examinations should be conducted annually to monitor
pre-existing and new skin pigmentary lesions before and during
treatment with setmelanotide.
Heart rate and blood pressure
monitoring: Heart rate and blood pressure should be
monitored as part of standard clinical practice at each medical
visit (at least every 6 months) for patients treated with
setmelanotide.
Prolonged penile erection: Spontaneous
penile erections have been reported in clinical trials with
setmelanotide. Patients who have a penile erection lasting longer
than 4 hours should be instructed to seek emergency medical
attention for potential treatment of priapism.
Depression: In clinical trials, depression
has been reported in patients treated with setmelanotide. Patients
with depression should be monitored at each medical visit during
treatment with setmelanotide. Consideration should be given to
discontinuing setmelanotide if patients experience suicidal
thoughts or behaviors.
Pediatric Population: The prescribing
physician should periodically assess response to setmelanotide
therapy. In growing children, the impact of weight loss on growth
and maturation should be evaluated. The prescribing physician
should monitor growth (height and weight) using age- and
sex-appropriate growth curves.
Excipients: This medicinal product
contains 10 mg benzyl alcohol in each ml. Benzyl alcohol may cause
allergic reactions. Patients who are pregnant or breastfeeding
should be advised of the potential risk from the excipient benzyl
alcohol, which might accumulate over time and cause metabolic
acidosis. This medicinal product should be used with caution in
patients with hepatic or renal impairment, because of the potential
risk from the excipient benzyl alcohol which might accumulate over
time and cause metabolic acidosis.
Sodium: This medicinal product contains
less than 1 mmol sodium (23 mg) per dose, that is to say
essentially “sodium-free.”
ADVERSE REACTIONSThe most frequent adverse
reactions are hyperpigmentation (51%), injection site reaction
(39%), nausea (33%), and headache (26%).
USE IN SPECIFIC POPULATIONS
PregnancyThere are no data from the use of
setmelanotide in pregnant women. Animal studies do not indicate
direct harmful effects with respect to reproductive toxicity.
However, administration of setmelanotide to pregnant rabbits
resulted in decreased maternal food consumption leading to
embryo-fetal effects. As a precautionary measure, setmelanotide
should not be started during pregnancy or while attempting to get
pregnant as weight loss during pregnancy may result in fetal harm.
If a patient who is taking setmelanotide has reached a stable
weight and becomes pregnant, consideration should be given to
maintaining setmelanotide treatment as there was no proof of
teratogenicity in the nonclinical data. If a patient who is taking
setmelanotide and still losing weight gets pregnant, setmelanotide
should either be discontinued, or the dose reduced while monitoring
for the recommended weight gain during pregnancy. The treating
physician should carefully monitor weight during pregnancy in a
patient taking setmelanotide.
Breast-feedingIt is unknown whether
setmelanotide is excreted in human milk. A nonclinical study showed
that setmelanotide is excreted in the milk of nursing rats. No
quantifiable setmelanotide concentrations were detected in plasma
from nursing pups. A risk to the newborn/infant cannot be excluded.
A decision must be made whether to discontinue breastfeeding or to
discontinue/abstain from setmelanotide therapy taking into account
the benefit of breastfeeding for the child and the benefit of
therapy for the mother.
FertilityNo human data on the effect of
setmelanotide on fertility are available. Animal studies did not
indicate harmful effects with respect to fertility.
To report SUSPECTED ADVERSE REACTIONS, contact Rhythm
Pharmaceuticals at +1 (833) 789-6337. See Summary of
Product Characteristics’ APPENDIX V for a list of
European national reporting systems to communicate adverse
reactions.
Please see the full Prescribing Information for
additional Important Safety Information.
Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements contained in this press release
that do not relate to matters of historical fact should be
considered forward-looking statements, including without limitation
statements regarding the safety, efficacy, and regulatory and
clinical design or progress, potential regulatory submissions,
approvals and timing thereof of setmelanotide and LB54640,
including our Phase 3 trial of setmelanotide for patients with
hypothalamic obesity and Phase 2 SIGNAL trial, the potential
benefits of setmelanotide for patients with hypothalamic obesity,
our expectations surrounding potential regulatory submissions,
approvals and timing thereof, including the sNDA for the label
expansion of IMCIVREE, the Company’s business strategy and plans,
including regarding commercialization of setmelanotide, our
anticipated financial performance and financial position, including
estimated Non-GAAP Operating Expenses for the year ending December
31, 2024, and the sufficiency of our cash, cash equivalents and
short-term investments to fund our operations. Statements using
words such as “expect”, “anticipate”, “believe”, “may”, “will”,
“aim” and similar terms are also forward-looking statements. Such
statements are subject to numerous risks and uncertainties,
including, but not limited to, our ability to enroll patients in
clinical trials, the design and outcome of clinical trials, the
ability to achieve necessary regulatory approvals, risks associated
with data analysis and reporting, failure to identify and develop
additional product candidates, unfavorable pricing regulations,
third-party reimbursement practices or healthcare reform
initiatives, risks associated with the laws and regulations
governing our international operations and the costs of any related
compliance programs, the impact of competition, risks relating to
product liability lawsuits, inability to maintain collaborations,
or the failure of these collaborations, our reliance on third
parties, risks relating to intellectual property, our ability to
hire and retain necessary personnel, general economic conditions,
risks related to internal control over financial reporting, and the
other important factors discussed under the caption “Risk Factors”
in our Annual Report on Form 10-K for the year ended December 31,
2023 and our other filings with the Securities and Exchange
Commission. Except as required by law, we undertake no obligations
to make any revisions to the forward-looking statements contained
in this press release or to update them to reflect events or
circumstances occurring after the date of this press release,
whether as a result of new information, future developments or
otherwise.
Non-GAAP Financial
MeasuresThis press release includes Non-GAAP Operating
Expenses, a supplemental measure of our performance that is not
required by, or presented in accordance with, U.S. GAAP and should
not be considered as an alternative to operating expenses or any
other performance measure derived in accordance with GAAP.
We define Non-GAAP Operating Expenses
as GAAP operating expenses excluding stock-based compensation and
fixed consideration related to in-licensing.
We caution investors that amounts
presented in accordance with our definition of Non-GAAP Operating
Expenses may not be comparable to similar measures disclosed by our
competitors because not all companies and analysts calculate this
non-GAAP financial measure in the same manner. We present this
non-GAAP financial measure because we consider it to be an
important supplemental measure of our performance and believe it is
frequently used by securities analysts, investors, and other
interested parties in the evaluation of companies in our industry.
Management believes that investors’ understanding of our
performance is enhanced by including this non-GAAP financial
measure as a reasonable basis for comparing our ongoing results of
operations.
Management uses this non-GAAP
financial measure for planning purposes, including the preparation
of our internal annual operating budget and financial projections;
to evaluate the performance and effectiveness of our operational
strategies; and to evaluate our capacity to expand our business.
This non-GAAP financial measure has limitations as an analytical
tool, and should not be considered in isolation, or as an
alternative to, or a substitute for operating expenses or other
financial statement data presented in accordance with GAAP in our
consolidated financial statements.
Rhythm has not provided a quantitative
reconciliation of forecasted Non-GAAP Operating Expenses to
forecasted GAAP operating expenses because the Company is unable,
without making unreasonable efforts, to calculate stock-based
compensation expenses. These items, which could materially affect
the computation of forward-looking GAAP operating expenses, are
inherently uncertain and depends on various factors, some of which
are outside of Rhythm's control.
Corporate
Contact:David ConnollyExecutive Director, Investor
Relations and Corporate CommunicationsRhythm Pharmaceuticals,
Inc.857-264-4280dconnolly@rhythmtx.com
Media Contact:Adam
DaleyBerry & Company Public
Relations212-253-8881adaley@berrypr.com
|
Rhythm Pharmaceuticals, Inc.Condensed
Consolidated Statements of Operations and Comprehensive
Loss(in thousands, except share and per share
data)(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, |
|
|
|
2024 |
|
2023 |
Revenues: |
|
|
|
|
|
|
|
Product revenue, net |
|
|
$ |
25,967 |
|
|
$ |
11,469 |
|
License revenue |
|
|
|
— |
|
|
|
— |
|
Total revenues |
|
|
|
25,967 |
|
|
|
11,469 |
|
Costs and expenses: |
|
|
|
|
|
|
|
Cost of sales |
|
|
|
2,807 |
|
|
|
1,421 |
|
Research and development |
|
|
|
128,665 |
|
|
|
37,945 |
|
Selling, general, and administrative |
|
|
|
34,382 |
|
|
|
24,634 |
|
Total costs and expenses |
|
|
|
165,854 |
|
|
|
64,000 |
|
Loss from operations |
|
|
|
(139,887 |
) |
|
|
(52,531 |
) |
Other income (expense): |
|
|
|
|
|
|
|
Other income (expense), net |
|
|
|
524 |
|
|
|
(27 |
) |
Interest expense |
|
|
|
(4,755 |
) |
|
|
(3,061 |
) |
Interest income |
|
|
|
3,046 |
|
|
|
3,440 |
|
Total other income (expense), net |
|
|
|
(1,185 |
) |
|
|
352 |
|
Loss before income taxes |
|
|
|
(141,072 |
) |
|
|
(52,179 |
) |
Provision for income
taxes |
|
|
|
300 |
|
|
|
— |
|
Net loss |
|
|
$ |
(141,372 |
) |
|
$ |
(52,179 |
) |
Net loss per share, basic and diluted |
|
|
$ |
(2.35 |
) |
|
$ |
(0.92 |
) |
Weighted-average common shares outstanding, basic and diluted |
|
|
|
60,143,558 |
|
|
|
56,708,975 |
|
|
|
|
|
|
|
|
|
Other comprehensive loss: |
|
|
|
|
|
|
|
Net loss |
|
|
$ |
(141,372 |
) |
|
$ |
(52,179 |
) |
Foreign currency translation adjustment |
|
|
|
(71 |
) |
|
|
21 |
|
Unrealized gain (loss), net on marketable securities |
|
|
|
(244 |
) |
|
|
65 |
|
Comprehensive loss |
|
|
$ |
(141,687 |
) |
|
$ |
(52,093 |
) |
|
|
Rhythm Pharmaceuticals, Inc.Condensed Consolidated Balance
Sheets(in thousands, except share and per share
data)(Unaudited) |
|
|
|
|
|
|
|
|
|
|
March 31, |
|
December 31, |
|
|
2024 |
|
2023 |
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
53,428 |
|
|
$ |
60,081 |
|
Short-term investments |
|
|
147,771 |
|
|
|
215,765 |
|
Accounts receivable, net |
|
|
14,695 |
|
|
|
14,867 |
|
Inventory |
|
|
8,507 |
|
|
|
8,624 |
|
Prepaid expenses and other current assets |
|
|
11,352 |
|
|
|
8,931 |
|
Total current assets |
|
|
235,753 |
|
|
|
308,268 |
|
Property and equipment,
net |
|
|
1,149 |
|
|
|
1,341 |
|
Right-of-use asset |
|
|
670 |
|
|
|
781 |
|
Intangible assets, net |
|
|
6,815 |
|
|
|
7,028 |
|
Restricted cash |
|
|
460 |
|
|
|
328 |
|
Other long-term assets |
|
|
13,804 |
|
|
|
14,999 |
|
Total assets |
|
$ |
258,651 |
|
|
$ |
332,745 |
|
Liabilities and
stockholders’ equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
7,550 |
|
|
$ |
4,885 |
|
Accrued expenses and other current liabilities |
|
|
44,545 |
|
|
|
48,262 |
|
Deferred revenue |
|
|
1,286 |
|
|
|
1,286 |
|
Lease liability |
|
|
793 |
|
|
|
770 |
|
Total current liabilities |
|
|
54,174 |
|
|
|
55,203 |
|
Long-term liabilities: |
|
|
|
|
|
|
Deferred royalty
obligation |
|
|
107,355 |
|
|
|
106,143 |
|
Lease liability,
non-current |
|
|
284 |
|
|
|
490 |
|
Derivative liability |
|
|
660 |
|
|
|
1,150 |
|
Other Long Term
Liabilities |
|
|
34,597 |
|
|
|
— |
|
Total liabilities |
|
|
197,070 |
|
|
|
162,986 |
|
Commitments and contingencies
(Note 12) |
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
Preferred Stock, $0.001 par value: 10,000,000 shares authorized; no
shares issued and outstanding at March 31, 2024 and
December 31, 2023 |
|
|
— |
|
|
|
— |
|
Common stock, $0.001 par value: 120,000,000 shares authorized;
60,964,468 and 59,426,559 shares issued and outstanding at
March 31, 2024 and December 31, 2023,
respectively |
|
|
60 |
|
|
|
59 |
|
Additional paid-in capital |
|
|
1,097,810 |
|
|
|
1,064,302 |
|
Accumulated other comprehensive income (loss) |
|
|
(181 |
) |
|
|
134 |
|
Accumulated deficit |
|
|
(1,036,108 |
) |
|
|
(894,736 |
) |
Total stockholders’ equity |
|
|
61,581 |
|
|
|
169,759 |
|
Total liabilities and stockholders’ equity |
|
$ |
258,651 |
|
|
$ |
332,745 |
|
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From Sep 2024 to Oct 2024
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From Oct 2023 to Oct 2024